{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:53:08Z","timestamp":1788007988593,"version":"build-2784847793"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Subclinical, device-detected atrial fibrillation (AF) is frequently recorded by pacemakers and other implanted cardiac rhythm devices. Patients with device-detected AF have an elevated risk of stroke, but a lower risk of stroke than similar patients with clinical AF captured with surface electrocardiogram. Two randomized clinical trials (NOAH-AFNET 6 and ARTESiA) have tested a direct oral anticoagulant (DOAC) against aspirin or placebo. A study-level meta-analysis of the two trials found that treatment with a DOAC resulted in a 32% reduction in ischaemic stroke and a 62% increase in major bleeding; the results of the two trials were consistent. The annualized rate of stroke in the control arms was \u223c1%. Several factors point towards overall net benefit from DOAC treatment for patients with device-detected AF. Strokes in ARTESiA were frequently fatal or disabling and bleeds were rarely lethal. The higher absolute rates of major bleeding compared with ischaemic stroke while on treatment with a DOAC in the two trials are consistent with the ratio of bleeds to strokes seen in the pivotal DOAC vs. warfarin trials in patients with clinical AF. Prior research has concluded that patients place a higher emphasis on stroke prevention than on bleeding. Further research is needed to identify the characteristics that will help identify patients with device-detected AF who will receive the greatest benefit from DOAC treatment.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae075","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T21:16:36Z","timestamp":1722546996000},"page":"iv4-iv11","source":"Crossref","is-referenced-by-count":6,"title":["Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-7542","authenticated-orcid":false,"given":"William F","family":"McIntyre","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton St East, Hamilton, Ontario, L8L 2X2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-1266","authenticated-orcid":false,"given":"Alexander P","family":"Benz","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton St East, Hamilton, Ontario, L8L 2X2 , Canada"},{"name":"Department of Cardiology, University Medical Centre Mainz, Johannes Gutenberg-University, Mainz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedim","family":"Tojaga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Esbjerg and Grindsted Hospital\u2014University Hospital of Southern Denmark , Esbjerg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9145-6887","authenticated-orcid":false,"given":"Axel","family":"Brandes","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Esbjerg and Grindsted Hospital\u2014University Hospital of Southern Denmark , Esbjerg , Denmark"},{"name":"Department of Regional Health Research, University of Southern Denmark , Esbjerg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-7580","authenticated-orcid":false,"given":"Jeff S","family":"Healey","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton St East, Hamilton, Ontario, L8L 2X2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2024080110054963000_suae075-B1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(16)30968-0","article-title":"Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study","volume":"388","author":"Healey","year":"2016","journal-title":"Lancet"},{"key":"2024080110054963000_suae075-B2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024080110054963000_suae075-B3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2024080110054963000_suae075-B4","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2024080110054963000_suae075-B5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"2024080110054963000_suae075-B6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15420\/aer.2018.18.2","article-title":"Risk factor management in atrial fibrillation","volume":"7","author":"Brandes","year":"2018","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"2024080110054963000_suae075-B7","doi-asserted-by":"crossref","first-page":"ii52","DOI":"10.1093\/europace\/euaa346","article-title":"Risk factor management and atrial fibrillation","volume":"23","author":"Hendriks","year":"2021","journal-title":"Europace"},{"key":"2024080110054963000_suae075-B8","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1161\/CIR.0000000000000748","article-title":"Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association","volume":"141","author":"Chung","year":"2020","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","article-title":"The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study","volume":"2","author":"Glotzer","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2024080110054963000_suae075-B10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.117.028845","article-title":"Subclinical atrial fibrillation in older patients","volume":"136","author":"Healey","year":"2017","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B12","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","article-title":"Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST)","volume":"107","author":"Glotzer","year":"2003","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ahj.2004.06.032","article-title":"Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"Flaker","year":"2005","journal-title":"Am Heart J"},{"key":"2024080110054963000_suae075-B14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/STROKEAHA.109.571455","article-title":"Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events","volume":"41","author":"Ziegler","year":"2010","journal-title":"Stroke"},{"key":"2024080110054963000_suae075-B15","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"2024080110054963000_suae075-B16","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1161\/CIR.0000000000000568","article-title":"Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association","volume":"137","author":"Chen","year":"2018","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.hrthm.2018.10.006","article-title":"Global disparities in cardiac pacemaker therapy: problem statement, potential solution, and call to action","volume":"16","author":"Marine","year":"2019","journal-title":"Heart Rhythm"},{"key":"2024080110054963000_suae075-B18","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamacardio.2017.3180","article-title":"Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF study","volume":"2","author":"Reiffel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2024080110054963000_suae075-B19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.hrthm.2017.04.026","article-title":"Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) study","volume":"14","author":"Nasir","year":"2017","journal-title":"Heart Rhythm"},{"key":"2024080110054963000_suae075-B20","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"2024080110054963000_suae075-B21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin in anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024080110054963000_suae075-B22","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/europace\/eux163","article-title":"Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)","volume":"19","author":"Chair","year":"2017","journal-title":"Europace"},{"key":"2024080110054963000_suae075-B23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2017.04.008","article-title":"Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial","volume":"189","author":"Lopes","year":"2017","journal-title":"Am Heart J"},{"key":"2024080110054963000_suae075-B25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2017.04.015","article-title":"Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial","volume":"190","author":"Kirchhof","year":"2017","journal-title":"Am Heart J"},{"key":"2024080110054963000_suae075-B26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke prevention in atrial fibrillation study: final results","volume":"84","author":"McBride","year":"1991","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian atrial fibrillation anticoaguiation (CAFA) study","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"2024080110054963000_suae075-B28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","year":"1990","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1056\/NEJM199003223221232","article-title":"Preliminary report of the stroke prevention in atrial fibrillation study","volume":"322","year":"1990","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"European Atrial Fibrillation Trial","year":"1993","journal-title":"Lancet"},{"key":"2024080110054963000_suae075-B32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B35","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B36","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2024080110054963000_suae075-B37","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"ACTIVE Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"2024080110054963000_suae075-B41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"149","author":"McIntyre","year":"2023","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B42","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1161\/CIRCULATIONAHA.118.038988","article-title":"Practice variation in anticoagulation prescription and outcomes after device-detected atrial fibrillation","volume":"139","author":"Perino","year":"2019","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B43","first-page":"14","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B44","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur Heart J"},{"key":"2024080110054963000_suae075-B45","doi-asserted-by":"crossref","first-page":"e003998","DOI":"10.1161\/CIRCOUTCOMES.117.003998","article-title":"Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)","volume":"11","author":"Aisenberg","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2024080110054963000_suae075-B46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"key":"2024080110054963000_suae075-B47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ahj.2023.03.012","article-title":"Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores","volume":"261","author":"Hijazi","year":"2023","journal-title":"Am Heart J"},{"key":"2024080110054963000_suae075-B48","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080110054963000_suae075-B49","first-page":"109","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee Members","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024080110054963000_suae075-B50","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"2024080110054963000_suae075-B51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","article-title":"Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis","volume":"39","author":"Mahajan","year":"2018","journal-title":"Eur Heart J"},{"key":"2024080110054963000_suae075-B52","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"ASsessment of the cha2ds2-vasc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"key":"2024080110054963000_suae075-B53","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/eurjpc\/zwab018","article-title":"Utility of the CHA2DS2-VASc score for predicting ischaemic stroke in patients with or without atrial fibrillation: a systematic review and meta-analysis","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2024080110054963000_suae075-B54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","author":"Vanassche","year":"2015","journal-title":"Eur Heart J"},{"key":"2024080110054963000_suae075-B55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamacardio.2018.1176","article-title":"Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation","volume":"3","author":"Go","year":"2018","journal-title":"JAMA Cardiology"},{"key":"2024080110054963000_suae075-B56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamacardio.2018.1205","article-title":"When low-risk atrial fibrillation is not so low risk: beast of burden","volume":"3","author":"Steinberg","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2024080110054963000_suae075-B57","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/pace.14857","article-title":"Long duration of atrial high-rate episode is more favorable in predicting ischemic stroke than high CHA(2) DS(2) -VASc score","volume":"46","author":"Ding","year":"2023","journal-title":"Pacing Clin Electrophysiol"},{"key":"2024080110054963000_suae075-B58","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","article-title":"Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score","volume":"140","author":"Kaplan","year":"2019","journal-title":"Circulation"},{"key":"2024080110054963000_suae075-B59","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/STROKEAHA.110.609297","article-title":"Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring","volume":"42","author":"Boriani","year":"2011","journal-title":"Stroke"},{"key":"2024080110054963000_suae075-B60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events","volume":"20","author":"Botto","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024080110054963000_suae075-B61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/STROKEAHA.115.012004","article-title":"Atrial fibrillation and mechanisms of stroke: time for a new model","volume":"47","author":"Kamel","year":"2016","journal-title":"Stroke"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_4\/iv4\/58711299\/suae075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_4\/iv4\/58711299\/suae075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T21:17:11Z","timestamp":1722547031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/26\/Supplement_4\/iv4\/7725444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":61,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae075","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7]]}}}